Pioglitazone and Quetiapine XR Pharmacogenetic Study



Status:Completed
Conditions:Depression, Depression, Major Depression Disorder (MDD), Psychiatric, Bipolar Disorder
Therapuetic Areas:Psychiatry / Psychology, Pulmonary / Respiratory Diseases
Healthy:No
Age Range:18 - Any
Updated:4/21/2016
Start Date:February 2011
End Date:May 2015

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

Pharmacogenetic Study of Pioglitazone and Quetiapine XR Treatment Response in Mood Disorders

Obtain phenotypic data and a DNA/blood sample from mood disorder patients undergoing
pioglitazone or quetiapine XR treatment as a part of an IRB approved clinical trial
conducted at the Mood Disorders Program. Pioglitazone treatment is examined in metabolic
syndrome comorbid with bipolar depression (IRB # 07-08-24) and unipolar depression (IRB #
07-07-20). Quetiapine XR treatment is examined in generalized anxiety disorder comorbid with
bipolar depression (IRB # 10-06-19) and unipolar depression (IRB # 12-01-29). Please refer
to the respective IRB protocols for more information.


Inclusion Criteria:

- Must have participated in IRB protocols 10-06-19, 12-07-29, 07-07-20, and 07-08-24

- Patient must give consent to participate, sign and date the IRB approved written
informed consent form prior to the initiation of any procedures for this study

- Patient must be diagnosed with Bipolar Disorder or Major Depressive Disorder

- Patient must be at least 18 years old

- Patient must be willing to give a blood sample

Exclusion Criteria:

- Patient lacks the capacity to provide informed consent
We found this trial at
1
site
University Hospitals at Case Medical Center
Cleveland, Ohio 44194
?
mi
from
Cleveland, OH
Click here to add this to my saved trials